Evidence map›Paper›PMID 37608672›Full record

ArticleCurrent computer-aided drug design2024

Banxia Xiexin Decoction Prevents HT22 Cells from High Glucose-induced Neurotoxicity

Yinli Shi, Pei Sheng, Ming Guo, Kai Chen, Yun Zhao, Xu Wang, Mianhua Wu, Bo Li

Abstract read
PubMed Publisher
In one paragraph

Article in Current computer-aided drug design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. The role of Foxo3a in neuron-mediated cognitive impairment.Frontiers in molecular neuroscience · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yinli ShiThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Pei ShengThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Ming GuoSoutheast University, Zhongda Hospital Southeast University, Nanjing, China.
Kai ChenThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Yun ZhaoThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Xu WangThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Mianhua WuThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Bo LiThe First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Nanjing University of Chinese Medicine · CNZhongda Hospital Southeast University · CN

Funding

National Natural Science Foundation of China 81973796Research and Practice Innovation Program for Postgraduates in Jiangsu Province SJCX21_0725Wu Mian Hua Inheritance Studio of National Famous and Old Chinese Medicine Experts (2022) 75
6 · The paper itself

Abstract

backgroundType 2 diabetes-associated cognitive dysfunction (DCD) is a chronic complication of diabetes that has gained international attention. The medicinal compound Banxia Xiexin Decoction (BXXXD) from traditional Chinese medicine (TCM) has shown potential in improving insulin resistance, regulating endoplasmic reticulum stress (ERS), and inhibiting cell apoptosis through various pathways. However, the specific mechanism of action and medical value of BXXXD remain unclear.

methodsWe utilized TCMSP databases to screen the chemical constituents of BXXXD and identified DCD disease targets through relevant databases. By using Stitch and String databases, we imported the data into Cytoscape 3.8.0 software to construct a protein-protein interaction (PPI) network and subsequently identified core targets through network topology analysis. The core targets were subjected to Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. The results were further validated through in vitro experiments.

resultsNetwork pharmacology analysis revealed the screening of 1490 DCD-related targets and 190 agents present in BXXXD. The topological analysis and enrichment analysis conducted using Cytoscape software identified 34 core targets. Additionally, GO and KEGG pathway analyses yielded 104 biological targets and 97 pathways, respectively. BXXXD exhibited its potential in treating DCD by controlling synaptic plasticity and conduction, suppressing apoptosis, reducing inflammation, and acting as an antioxidant. In a high glucose (HG) environment, the expression of JNK, Foxo3a, SIRT1, ATG7, Lamp2, and LC3 was downregulated. BXXXD intervention on HT22 cells potentially involved inhibiting excessive oxidative stress, promoting neuronal autophagy, and increasing the expression levels of JNK, SIRT1, Foxo3a, ATG7, Lamp2, and LC3. Furthermore, the neuroprotective effect of BXXXD was partially blocked by SP600125, while quercetin enhanced the favorable role of BXXXD in the HG environment.

conclusionBXXXD exerts its effects on DCD through multiple components, targets, levels, and pathways. It modulates the JNK/SIRT1/Foxo3a signaling pathway to mitigate autophagy inhibition and apoptotic damage in HT22 cells induced by HG. These findings provide valuable perspectives and concepts for future clinical trials and fundamental research.

Indexed as

Drugs, Chinese HerbalForkhead Box Protein O3GlucoseSignal TransductionSirtuin 1AnimalsApoptosisCell LineMiceNeuroprotective Agentsbanxia xiexin decoctionDrugs, Chinese HerbalForkhead Box Protein O3FoxO3 protein, mouseGlucoseNeuroprotective AgentsSirt1 protein, mouseSirtuin 1apoptosisautophagyBanxia Xiexin decoctionbioinformaticsdiabetic cognitive dysfunctionJNK/SIRT1/Foxo3a.

Identifiers

PMID37608672
OpenAlexW4386084822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.